Dynamic Advisor Solutions LLC Buys 3,691 Shares of Astrazeneca Plc $AZN

Dynamic Advisor Solutions LLC grew its stake in Astrazeneca Plc (NYSE:AZN) by 25.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 18,196 shares of the company’s stock after purchasing an additional 3,691 shares during the period. Dynamic Advisor Solutions LLC’s holdings in Astrazeneca were worth $1,673,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Bank of Montreal Can increased its position in Astrazeneca by 344.6% during the 3rd quarter. Bank of Montreal Can now owns 3,478,114 shares of the company’s stock worth $266,841,000 after purchasing an additional 2,695,793 shares in the last quarter. Fayez Sarofim & Co boosted its position in Astrazeneca by 173.4% in the second quarter. Fayez Sarofim & Co now owns 3,745,902 shares of the company’s stock valued at $261,764,000 after buying an additional 2,376,032 shares in the last quarter. Holocene Advisors LP boosted its position in Astrazeneca by 41.8% in the third quarter. Holocene Advisors LP now owns 6,129,194 shares of the company’s stock valued at $470,232,000 after buying an additional 1,807,565 shares in the last quarter. Raymond James Financial Inc. grew its stake in shares of Astrazeneca by 64.8% during the second quarter. Raymond James Financial Inc. now owns 3,783,251 shares of the company’s stock worth $264,373,000 after buying an additional 1,487,662 shares during the last quarter. Finally, Bank of America Corp DE grew its stake in shares of Astrazeneca by 4.7% during the third quarter. Bank of America Corp DE now owns 32,633,139 shares of the company’s stock worth $2,503,614,000 after buying an additional 1,461,786 shares during the last quarter. 20.35% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently commented on AZN shares. Weiss Ratings assumed coverage on Astrazeneca in a research note on Wednesday, March 11th. They issued a “buy (b)” rating for the company. TD Cowen restated a “buy” rating on shares of Astrazeneca in a research report on Wednesday, March 18th. Citigroup began coverage on Astrazeneca in a report on Tuesday, January 27th. They issued a “buy” rating for the company. Wall Street Zen upgraded Astrazeneca from a “hold” rating to a “buy” rating in a research report on Friday, March 20th. Finally, Morgan Stanley reissued an “overweight” rating and set a $103.00 price target on shares of Astrazeneca in a research note on Wednesday, December 3rd. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $95.75.

Astrazeneca Price Performance

AZN stock opened at $185.54 on Wednesday. The stock has a market capitalization of $287.75 billion, a PE ratio of 31.96, a price-to-earnings-growth ratio of 1.39 and a beta of 0.32. The company has a debt-to-equity ratio of 0.51, a current ratio of 0.94 and a quick ratio of 0.72. Astrazeneca Plc has a 1-year low of $122.48 and a 1-year high of $212.71.

Astrazeneca Announces Dividend

The firm also recently announced a dividend, which was paid on Monday, March 23rd. Shareholders of record on Friday, February 20th were issued a $1.595 dividend. This represents a yield of 156.0%. The ex-dividend date was Friday, February 20th. Astrazeneca’s payout ratio is presently 74.83%.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.